Uterine Corpus Carcinosarcoma
Information
- Disease name
- Uterine Corpus Carcinosarcoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02874430 | Active, not recruiting | Phase 2 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | June 8, 2016 | June 2023 |
| NCT01935934 | Active, not recruiting | Phase 2 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 29, 2013 | March 26, 2025 |
| NCT02020707 | Active, not recruiting | Phase 1 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | February 24, 2014 | June 30, 2025 |
| NCT00478426 | Completed | Phase 2 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 30, 2007 | February 12, 2019 |
| NCT03422198 | Recruiting | Phase 3 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | January 30, 2018 | October 31, 2029 |
| NCT05049538 | Recruiting | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers | June 18, 2019 | June 30, 2024 | |
| NCT05256225 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | November 16, 2022 | October 31, 2027 |